What Is ABBV Fair Value?
AbbVie Inc. (ABBV) fair value estimate using multiple valuation models, updated daily.
As of August 1, 2026, AbbVie Inc. (ABBV) has a composite fair value estimate of $424.82 based on four valuation models: DCF (47% weight), Graham Number (0% weight), PEG (33% weight), and DDM (20% weight). The current market price is $250.94, suggesting the stock is undervalued by 69.3%.
Data as of August 1, 2026 (today)
Composite Fair Value
Undervalued3 of 4 models$424.82
vs. current price of $250.94(+69.3%)
How Is ABBV Fair Value Calculated?
Four independent models estimate what ABBV is worth. Each uses different inputs and assumptions. The composite blends them by weight.
ABBV Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
47% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$267.38
+6.6%Fair Value
Inputs used
DDM (Dividend Discount Model)
20% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$726.99
+189.7%Undervalued
Inputs used
ABBV Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
0% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
N/A
Requires positive EPS and book value. AbbVie Inc. currently has negative earnings, so the Graham formula cannot be applied.
Inputs used
PEG (Price/Earnings to Growth)
33% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$397.87
+58.6%Undervalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $250.94 is 6.6% below this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $3.96B | $3.75B |
| Year 2 | $4.95B | $4.43B |
| Year 3 | $6.19B | $5.23B |
| Year 4 | $7.74B | $6.19B |
| Year 5 | $9.67B | $7.31B |
| Year 6 | $12.09B | $8.64B |
| Year 7 | $15.11B | $10.21B |
| Year 8 | $18.89B | $12.07B |
| Year 9 | $23.61B | $14.27B |
| Year 10 | $29.52B | $16.86B |
| Terminal Value | $928.39B | $530.34B |
What Are ABBV's Key Financial Metrics?
Earnings & Growth
Current Price
$250.94
EPS (TTM)
$3.54
Forward P/E
15.4
Profit Margin
9.8%
Cash & Balance Sheet
Free Cash Flow
0
EBITDA
30.8B
Book Value
-$3.77
Total Debt
72.9B
What Do Analysts Say About ABBV?
Low
$200.00
Average
$270.39
High
$328.00
Upside
+7.8%
ABBV Fair Value FAQ
What is the fair value of ABBV?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), ABBV's estimated fair value is $424.82. The stock is currently trading at $250.94, which makes it undervalued by our analysis.
How is ABBV's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is ABBV overvalued or undervalued?
Based on our analysis, ABBV is undervalued. The current price of $250.94 is 69.3% below our estimated fair value of $424.82.
What do Wall Street analysts say about ABBV?
28 analysts cover AbbVie Inc. with a consensus rating of "Buy." The average price target is $270.39, ranging from $200.00 to $328.00. This implies 7.8% upside from the current price.